The webinar is the first in a series of webinars supported by an unrestricted educational grant from Bristol Myers Squibb. 

April 6, 2021 | 12:00 - 1:00 PM ET

Moderator: Allison Hays, MD, FASE

Speakers: Theodore Abraham, MD, FASE; Carolyn Ho, MD; and John Symanski, MD, FASE

The goal of the HCM webinar (part 1) is to understand the utility of echocardiography in the diagnosis and prognosis of HCM. In addition, the aim of the webinar is to review when the sonographer or echo reviewer should suspect HCM and what elements of the exam are most important in echo reporting.

Learning Objectives:

• To describe the utility of echocardiography in the diagnosis and prognosis of HCM (quantifying LVOT gradients, MR and LVEF)

• To review when the sonographer/echo reviewer should suspect HCM and what elements of the exam are most important in echo reporting

• To understand of the different patterns of HCM (such as apical variant) and when contrast should be used

• To identify pitfalls in gradient assessment (emphasis on dynamic nature of gradients, distinguishing LVOT from mid-cavity, or apical, and sub-valvular membranes). To distinguish between other conditions in which outflow obstruction may be encountered

• To understand the indications for stress testing in HCM patients, how to perform and interpret stress echocardiography for HCM

• Brief overview of medical treatment of HCM--Understand how echo can be used to monitor HCM patient's response to therapy over time

This activity is FREE for ASE Members and Nonmembers. This activity offers 1 CME credit. 

Disclosures: 

According to ACCME policy, ASE implemented mechanisms to resolve all conflicts of interest prior to the planning and implementation of this activity.

The following moderators/speakers reported no actual or potential conflicts of interest in relation to this activity:

• Allison Hays, MD, FASE
• Theodore Abraham, MD, FASE

The following moderators/speakers reported relationships with one or more commercial interests:

• John D. Symanski, MD, FASE; MyoKardia - Bristol Myers Squibb (Research Grant), (Advisory Board); Cytokinetics (Research Grant); Imbria Pharmaceuticals (Research Grant)
• Carolyn Ho, MD; MyoKardia (Consultant, Advisor); Tenaya (Consultant; Advisor)

The following CME reviewers and ASE Staff reported no actual or potential conflicts of interest in relation to this document: 

• Kathryn Lyons, ASE Healthcare Education Manager
• Rita France, RDCS, RDMS, RT, FASE
• Renee Bullock-Palmer, MD, FASE

• Contact:
  ASE Learning Hub